Full Text View
Tabular View
No Study Results Posted
Related Studies
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
This study has been completed.
Study NCT00904839   Information provided by Boehringer Ingelheim Pharmaceuticals

First Received on May 18, 2009.   Last Updated on June 27, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Colorectal Neoplasms
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Interventions listed in this trial
BIBF 1120
mFolfox
Bevacizumab
mFolfox 6
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services